L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012.

C. Marth, F. Landoni, S. Mahner, M. Mccormack, A. Gonzalez-martin et al., Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.29, issue.Supplement_4, p.262, 2018.

, Albert Einstein College of Medicine, analytical biological services, Barretos Cancer hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, et al integrated genomic and molecular characterization of cervical cancer, Cancer genome atlas research network, vol.543, pp.378-84, 201716.

P. A. Disilvestro, S. Ali, P. S. Craighead, J. A. Lucci, Y. Lee et al., Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a gynecologic oncology group study, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5, pp.458-64, 2014.

A. Sturdza, R. Pötter, L. U. Fokdal, C. Haie-meder, L. T. Tan et al., Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.120, issue.3, pp.428-461, 2016.

F. O. Gleber-netto, X. Rao, T. Guo, Y. Xi, M. Gao et al., Variations in HPV function are associated with survival in squamous cell carcinoma, JCI Insight, vol.4, issue.1, 2019.

C. Ngo, S. Samuels, K. Bagrintseva, A. Slocker, P. Hupé et al., From prospective biobanking to precision medicine: BIO-RAIDs -an EU study protocol in cervical cancer, BMC Cancer, vol.15, p.842, 2015.

S. Samuels, B. Balint, V. Der-leyen, H. Hupé, P. De-koning et al., Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study, Br J Cancer, vol.115, issue.12, pp.1575-83, 2016.

, World medical association declaration of Helsinki: ethical principles for medical research involving human subjects, World Medical Association, vol.310, issue.20, pp.2191-2195, 2013.

E. J. Emanuel, Reconsidering the declaration of Helsinki, Lancet Lond Engl, vol.381, issue.9877, pp.1532-1535, 2013.

R. Akbani, K. Becker, N. Carragher, T. Goldstein, L. De-koning et al., Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (reverse phase protein Array) society, Mol Cell Proteomics MCP, vol.13, issue.7, pp.1625-1668, 2014.

S. Troncale, A. Barbet, L. Coulibaly, E. Henry, B. He et al., NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data, PloS One, vol.7, issue.6, p.38686, 2012.

N. Bhatla, D. Aoki, D. N. Sharma, and R. Sankaranarayanan, Cancer of the cervix uteri, Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet, vol.143, pp.22-36, 2018.

A. De-la-rochefordiere, M. Kamal, A. Floquet, L. Thomas, P. Petrow et al., PIK3CA pathway mutations predictive of poor response following standard Radiochemotherapy ± Cetuximab in cervical Cancer patients, Clin Cancer Res Off J Am Assoc Cancer Res, vol.21, issue.11, pp.2530-2537, 2015.

A. I. Ojesina, L. Lichtenstein, S. S. Freeman, C. S. Pedamallu, I. Imaz-rosshandler et al., Landscape of genomic alterations in cervical carcinomas, Nature, vol.506, issue.7488, pp.371-376, 2014.

A. Bahrami, M. Hasanzadeh, S. M. Hassanian, S. Shahidsales, M. Ghayour-mobarhan et al., The potential value of the PI3K/Akt/mTOR signaling pathway for assessing prognosis in cervical cancer and as a target for therapy, J Cell Biochem, vol.118, issue.12, pp.4163-4172, 2017.

D. A. Fruman, H. Chiu, B. D. Hopkins, S. Bagrodia, L. C. Cantley et al., The PI3K pathway in human disease, Cell, vol.170, issue.4, pp.605-640, 2017.

I. M. Berenjeno, R. Piñeiro, S. D. Castillo, W. Pearce, N. Mcgranahan et al., Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling, Nat Commun, vol.8, issue.1, p.24, 20171773.

D. Juric, J. S. De-bono, P. M. Lorusso, J. Nemunaitis, E. I. Heath et al., A first-inhuman, phase I, dose-escalation study of TAK-117, a selective PI3K? isoform inhibitor, in patients with advanced solid malignancies, Clin Cancer Res Off J Am Assoc Cancer Res, vol.23, issue.17, pp.5015-5038, 2017.

D. M. Roy, L. A. Walsh, and T. A. Chan, Driver mutations of cancer epigenomes, Protein Cell, vol.5, issue.4, pp.265-96, 2014.

P. A. Marks, Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions, Biochim Biophys Acta, vol.12, issue.10, pp.717-742, 1799.

S. Minucci and P. G. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nat Rev Cancer, vol.6, issue.1, pp.38-51, 2006.

N. S. Banerjee, D. W. Moore, and T. R. Broker, Vorinostat Chow LT. A pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification, Proc Natl Acad Sci U S A, vol.115, issue.47, pp.11138-11185, 2018.

J. Frenel, L. Tourneau, C. , O. Neil, B. Ott et al., Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical Cancer: results from the phase Ib KEYNOTE-028 trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, issue.36, pp.4035-4076, 2017.

S. F. Bakhoum, B. Ngo, A. M. Laughney, J. Cavallo, C. J. Murphy et al., Chromosomal instability drives metastasis through a cytosolic DNA response, Nature, vol.553, issue.7689, pp.467-72, 201825.

X. Yang, G. T. Chen, Y. Q. Wang, S. Xian, L. Zhang et al., TLR4 promotes the expression of HIF-1? by triggering reactive oxygen species in cervical cancer cells in vitro-implications for therapeutic intervention, Mol Med Rep, vol.17, issue.2, pp.2229-2267, 2018.

M. Terranova-barberio, S. Thomas, N. Ali, N. Pawlowska, J. Park et al., HDAC inhibition potentiates immunotherapy in triple negative breast cancer, Oncotarget, vol.8, issue.69, pp.114156-72, 2017.